Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Insurer And Patient Drug Costs Soared For Top-Sellers Over 6-Year Study

Executive Summary

Median out-of-pocket and insurance costs for 49 high-volume brand-name drugs jumped 79% from 2012 to 2017 in a new analysis of 35m individual insurance claims published in JAMA Network. Competition did not correlate to lower costs.

You may also be interested in...



One More Score: CBO Projects HHS Rebate Proposal Would Boost Part D Spending $170bn

HHS downplays latest attempt to predict “complex behavior changes to a broken system.”

Industry's Drug Pricing Power Is Running On Fumes

Pharma is facing a big headwind in 2019 in the form of diminished drug pricing power. The pricing trend puts net drug prices squarely in the red for most large pharma manufacturers, but US lawmakers aren't likely to be reassured heading into an upcoming hearing on drug pricing.

Enhertu Poised To Rewrite The Standard Of Care After ESMO

AstraZeneca/Daiichi Sankyo's Enhertu is poised to become the new standard of care for second-line HER2-positive breast cancer after handedly beating Roche's Kadcyla on PFS.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125334

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel